SonoVascular, Inc.

Thank you to #NCBiotech for hosting a successful Triangle Venture Day! We appreciated the opportunity to have Jacob Ruprecht share our exciting progress with investors and strategic partners and further connect with the medtech ecosystem in the RTP community.  #medtech #innovation #medtechstartups #Partnership #MedicalTechnology #thrombectomy #VTE

SonoVascular, Inc. has announced the successful initiation of its first-in-human study of the company’s SonoThrombectomy system, an ultrasound-facilitated, thrombolytic-enhanced platform that utilises multiple mechanisms of action to treat patients with venous thromboembolism (#VTE). The catheter-based system combines microbubble-mediated cavitation with low-dose thrombolytic delivery to treat clots with no blood loss. Read more: https://lnkd.in/ebCMhM28

SonoVascular, Inc. has announced the successful initiation of its first-in-human study (FIH) of the company’s SonoThrombectomy system, an ultrasound-facilitated, thrombolytic-enhanced platform that utilises multiple mechanisms of action to treat patients with venous thromboembolism (#VTE). Albrecht Krämer Hospital Dipreca https://t.ly/kJwCd

SonoVascular is excited to announce that our First-In-Human case with the SonoThrombectomy System was successfully completed by Dr. Manuel Espíndola, Dr. Albrecht Krämer and their clinical team at Hospital DIPRECA in Santiago, Chile, supported on-site by SonoVascular personnel and Bioscience staff (CRO). This major milestone is the first step in our mission to transform the treatment of venous thromboembolism. We wish to take a moment to thank all of our partners, without whom we could not have accomplished this pivotal achievement. We look forward to continuing to work with our extended team on our high-priority and focused journey. Read our full press release here: https://lnkd.in/eqvu-8nd #medtech #innovation #medtechstartups #medtechinnovator #MedicalTechnology #thrombectomy #VTE

We are grateful to have such a strong partner in the NCBiotech Center – thank you for your support! #medtech #medtechstartups #Partnership #DVT

We are thrilled to announce a strategic collaboration with Lantheus to use DEFINITY microbubbles in combination with SonoVascular's SonoThrombectomy System to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). Lantheus is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents, and DEFINITY is the leading ultrasound enhancing agent in the U.S. Since its launch in 2001, DEFINITY has been used in over 25 million imaging procedures throughout the world.    This collaboration presents an extraordinary opportunity to leverage Lantheus' proven microbubble solutions with our innovative SonoThrombectomy System, aiming to significantly enhance treatment outcomes for DVT and PE patients. We invite you to be a part of the journey with SonoVascular!   #medtech #innovation #healthtech #medtechstartups #medtechinnovator #Partnership #MedicalTechnology #DVT #PulmonaryEmbolism   https://lnkd.in/eaeHHrZE

We are thrilled to announce a strategic collaboration with Lantheus to use DEFINITY microbubbles in combination with SonoVascular's SonoThrombectomy System to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). Lantheus is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents, and DEFINITY is the leading ultrasound enhancing agent in the U.S. Since its launch in 2001, DEFINITY has been used in over 25 million imaging procedures throughout the world.    This collaboration presents an extraordinary opportunity to leverage Lantheus' proven microbubble solutions with our innovative SonoThrombectomy System, aiming to significantly enhance treatment outcomes for DVT and PE patients. We invite you to be a part of the journey with SonoVascular!   #medtech #innovation #healthtech #medtechstartups #medtechinnovator #Partnership #MedicalTechnology #DVT #PulmonaryEmbolism   https://lnkd.in/eaeHHrZE

Want to learn more about our novel pharmaco-mechanical thrombectomy approach?  Check out Venous News’ writeup of Dr. Marston presenting preclinical results of our venous thrombectomy solution during the 2024 American Venous Forum held earlier this year.  Our team looks forward to partnering with world class physicians such as Dr. Marston to bring this therapy into the clinic.   Thank you to Venous News for the profile! #medtech #innovation #healthtech #medtechstartups #medtechinnovator https://lnkd.in/g5PyCcNj

Want to learn more about our novel pharmaco-mechanical thrombectomy approach?  Check out Venous News’ writeup of Dr. Marston presenting preclinical results of our venous thrombectomy solution during the 2024 American Venous Forum held earlier this year.  Our team looks forward to partnering with world class physicians such as Dr. Marston to bring this therapy into the clinic.   Thank you to Venous News for the profile! #medtech #innovation #healthtech #medtechstartups #medtechinnovator https://lnkd.in/g5PyCcNj

Clot chronicity, that is, how the consistency of the clot changes as it ages, from a soft red blood cell-rich gob to a tough mass made of fibrin and collagen that adheres tightly to the vessel wall (the clot continuum is clinically categorized as acute, subacute, and chronic), would dictate a variety of removal strategies. Today, there are several on-label drug and thrombectomy strategies (see Figure 3). Devices for deep venous disease are having their day; the markets are becoming crowded. Second-generation movers must now find meaningful ways to differentiate themselves. MedTech Strategist interviews two companies with outside-the-box solutions: SonoVascular, Inc., in venous thrombectomy, and Auxetics, the developer of a novel venous stent. Part 2 of a 2-part review of the deep venous device market: https://bit.ly/3Vqn7XM #medtech #thrombectomy #deepvenous #venous